Back to Search
Start Over
Safety of Epicutaneous Immunotherapy in Peanut-Allergic Children: REALISE Randomized Clinical Trial Results
- Source :
- The Journal of Allergy and Clinical Immunology: In Practice; 20210101, Issue: Preprints
- Publication Year :
- 2021
-
Abstract
- Treatment options for peanut allergy are limited. In previous clinical trials, epicutaneous immunotherapy with a patch containing 250-μg peanut protein (Viaskin Peanut 250 μg [VP250]) was well tolerated and statistically superior to placebo in desensitizing peanut-allergic children.
Details
- Language :
- English
- ISSN :
- 22132198
- Issue :
- Preprints
- Database :
- Supplemental Index
- Journal :
- The Journal of Allergy and Clinical Immunology: In Practice
- Publication Type :
- Periodical
- Accession number :
- ejs58364901
- Full Text :
- https://doi.org/10.1016/j.jaip.2021.11.017